title: [The use of aflibercept (Eylea) in the treatment of polypoidal choroidal vasculopathy--case report].
abstract: The paper presents a case of a 25-year-old woman referred to the Outpatient Clinic at the Department of Ophthalmology, University Clinical Centre in Gdansk, with sudden vision impairment in her right eye. Clinical manifestation and diagnostic tests gave a basis for the preliminary diagnosis of polypoidal choroidal vasculopathy. Polypoidal choroidal vasculopathy is a type of choroidal neovascularisation, frequently confused with age-related macular degeneration. Standard treatment includes photodynamic therapy and intravitreal injections of anti-vascular endothelial growth factor agents. 2.0 miligrams of aflibercept was administered as an intravitreal injection, causing a rapid, significant improvement of visual function and proper anatomical relationships within the retina.
authors.forename: Paulina
authors.initials: P
authors.lastname: Glasner
authors.forename: Dorota
authors.initials: D
authors.lastname: Raczyńska
authors.forename: Leopold
authors.initials: L
authors.lastname: Glasner
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D002829:Choroid; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D010778:Photochemotherapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage* / Q000494:pharmacology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000494:pharmacology; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042442:Vascular Endothelial Growth Factors; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor